Abbott Receives FDA Authorization For Dual Glucose-Ketone Sensor

Abbott (ABT) said the U.S. FDA authorized its Libre Duo 10 Day system, described as the world’s first dual glucose/ketone sensing technology for people with diabetes. The regulatory approval is a positive product milestone that could support future adoption of Abbott’s diabetes monitoring platform, though the article provides no financial figures or guidance impact.